Statement of Organization, Functions, and Delegations of Authority, 9914-9915 [2010-4391]
Download as PDF
<![CDATA[
9914
Federal Register / Vol. 75, No. 42 / Thursday, March 4, 2010 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
Center for Outcomes and Evidence,
Agency for Healthcare Research and
Quality, (please see contact information
above).
Submission Criteria
The survey development teams are
interested in instruments and items
through which cancer patients can
assess the care they receive from
providers as well as the providers’
communication skill. They are also
interested in instruments and items
through which clinicians can assess
delivered care or communication. In
addition to survey items and
instruments, the development teams are
interested in observational measures
and their associated scoring systems.
AHRQ, in collaboration with
experienced investigators, will evaluate
all submitted instruments and items.
Instruments and items may be adopted
verbatim, in whole or in part, or may be
modified. AHRQ will assume
responsibility for the final measure sets
as well as any future modifications to
either survey.
Each voluntary submission should
include the following related
descriptive information, to the extent
that it is available:
• The name of the instrument (or
observational measure);
• Domain(s) or key concepts covered
in the survey;
• Language(s) in which the
instrument is available;
• Evidence of cultural/cross group
comparability;
• Cognitive screening or assessments
used and cognitive testing results;
• Method of selection of respondent
(i.e., patient) or patient representative or
spokesperson (i.e., most appropriate
family member/significant other, if more
than one available);
• Response rates;
• Cost estimates for data collection;
• Instrument reliability (internal
consistency, test-retest, etc.);
• Validity (content, construct,
criterion-related);
• Methods and results of field-testing;
and,
• Description of sampling strategies
and data collection protocols, including
such elements as mode of
administration, informed consent
materials, use of advance letters, timing
and frequencies of contacts;
• For the PCC initiative, indicate
whether the instrument (or
observational measure) is designed for
use with patients or clinicians, as well
as a statement indicating whether or not
the submitter wishes to be
acknowledged when the instrument is
published on the NCI Web site.
VerDate Nov<24>2008
16:39 Mar 03, 2010
Jkt 220001
In addition, a description of how
extensively the survey has been fielded
should also be included in the
submission materials. Measures that
have been tested or implemented in just
one or two research studies would have
more limited value than those tested or
implemented more widely, but
measures will be considered on an
individual basis when evaluating the
measures needing further testing as a
prerequisite to their inclusion in
CAHPS® or PCC draft and final survey
tools.
Submission of copies of existing
report formats developed to disclose
findings to consumers and providers is
desirable, but not required.
Additionally, information about existing
database(s) for the instrument(s)
submitted is helpful, but not required
for submission. Evidence of meeting the
validity, reliability, and other criteria
may be demonstrated through
submission of peer-reviewed journal
article(s) or through the best evidence
available at the time of submission.
SUPPLEMENTARY INFORMATION:
Background
AHRQ is a leader in developing and
testing instruments for quantitative
measurement of consumer experience
within the healthcare system of the
United States as evidenced by the
development and widespread use of
CAHPS® survey products. The
Consumer Assessment of Healthcare
Providers and Systems (CAHPS®)
program is a public-private initiative to
develop standardized surveys of patient
experience of care received in
ambulatory and facility settings.
Standardization of measures is essential
for meaningful comparison of
performance across providers and
settings. While CAHPS® instruments
have been highly regarded within the
industry and provide valuable
information, until now, no CAHPS®
condition-specific surveys have been
developed. Use of a standardized
measurement instrument for cancer care
will provide several benefits including:
Comparable information across cancer
care providers for the public about the
quality of care; data-based
recommendations for quality
improvement efforts and a data base to
stimulate further research in this area.
AHRQ, through a collaborative process
with NCI and other stakeholders, has
initiated the process for this project.
The steps to advance this initiative
are described below:
• Survey Development and Testing:
The process by which measures will be
defined and the most useful instruments
or measures identified is as follows:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Instruments submitted will be evaluated
by the project team in consultation with
AHRQ and NCI staff to determine if they
meet high priority or common
measurement needs and to identify
whether additional measure
development is required. Additional
measure development will be done as
needed.
Until the trademarked versions or
each instrument are available, access to
and use of draft versions will require
explicit written permission from AHRQ
and sharing of testing results with the
CAHPS® team. testing
• Implementation Plan: The final
tools and a description of the survey
process as well as instructions for
implementing of the final standardized
CAHPS® and PCC cancer care
instruments will be made available at no
cost to the public on AHRQ and NCI
Web sites and will include requirements
and information related to their use in
future data collections, analysis, and
public reporting.
Dated: February 16, 2010.
Carolyn M. Clancy,
Director, AHRQ.
[FR Doc. 2010–4387 Filed 3–3–10; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 75 FR 7489–7490, dated
February 19, 2010) is amended to reflect
the establishment of the Office of
Infectious Diseases, Centers for Disease
Control and Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows: After the mission statement for
the Centers for Disease Control and
Prevention (C), insert the following:
Office of Infectious Diseases (CV). The
mission of the Office of Infectious
Diseases (OID) is to lead, promote, and
facilitate science, programs, and policies
to reduce the burden of infectious
diseases in the United States and
globally.
Office of the Director (CVA). (1)
Serves as the principal advisor to the
E:\FR\FM\04MRN1.SGM
04MRN1
mstockstill on DSKH9S0YB1PROD with NOTICES
Federal Register / Vol. 75, No. 42 / Thursday, March 4, 2010 / Notices
CDC Director on infectious disease
issues; (2) assists the CDC Director in
formulating and communicating
strategic initiatives and policies; (3)
informs the CDC Director about key
infectious disease issues; (4) represents
the CDC Director externally on
infectious disease issues; (5) provides
strategic leadership to CDC’s infectious
disease national centers; (6) develops
overall strategic directions, sets
priorities, and promotes science,
policies, and programs related to
infectious diseases; (7) ensures that
agency-wide decisions on resource
allocation are aligned with infectious
disease priorities; (8) works with
infectious disease national centers,
other CDC centers and offices, and
public health partners to develop and
implement infectious disease goals and
objectives; (9) identifies infectious
disease issues of public health
importance and launches strategic
initiatives to address them, including
developing shared goals and monitoring
progress and accomplishments; (10)
recruits and supports an efficient,
effective, and vibrant work force, and
fosters a safe and healthy work
environment; (11) enhances
cooperation, collaboration, and
partnerships across multiple sectors,
domestically and globally; (12) ensures
integrity, transparency, and excellence
in public health science and practice;
(13) conducts ongoing evaluation and
adjustment of infectious disease
activities to ensure optimal effectiveness
and efficiency; (14) promotes an
environment that increases synergies
and efficiencies and reduces duplication
within CDC’s infectious disease
programs; and (15) provides direction
and leadership for external and internal
program reviews of the infectious
disease national centers’ initiatives,
performance, and achievements.
Influenza Coordination Unit (CVA4).
The mission of the Influenza
Coordination Unit (ICU) is to
synchronize all aspects of CDC’s
pandemic influenza preparedness and
response from strategy through
implementation and evaluation. In
carrying out its mission, the ICU: (1)
Serves as the principal advisor to the
CDC Director and Deputy Director for
Infectious Diseases on pandemic
influenza preparedness and response
activities, assisting the Director and
Deputy Director for Infectious Diseases
in formulating and communicating
strategic pandemic initiatives and
policies; (2) provides strategic
leadership for CDC in the areas of
pandemic preparedness and response,
including setting priorities and
VerDate Nov<24>2008
16:39 Mar 03, 2010
Jkt 220001
promoting science, policies, and
programs related to pandemic influenza;
(3) strategically manages a $150+
million budget and allocates funds
across the agency to ensure appropriate
resources for high priority areas; and (4)
conducts ongoing evaluation and
adjustment of pandemic preparedness
and response activities, in coordination
with the National Response Framework
and other emergency preparedness
guidance, to ensure optimal public
health effectiveness and efficient use of
human and fiscal resources.
Dated: February 23, 2010.
William P. Nichols,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2010–4391 Filed 3–3–10; 8:45 am]
BILLING CODE 4160–18–M
DEPARTMENT OF HOMELAND
SECURITY
Transportation Security Administration
[Docket No. TSA–2009–0018]
Extension of Agency Information
Collection Activity Under OMB Review:
Certified Cargo Screening Program
Transportation Security
Administration, DHS.
ACTION: 30-Day notice.
AGENCY:
SUMMARY: This notice announces that
the Transportation Security
Administration (TSA) has forwarded the
Information Collection Request (ICR),
OMB control number 1652–0053,
abstracted below to the Office of
Management and Budget (OMB) for
renewal in compliance with the
Paperwork Reduction Act. The ICR
describes the nature of the information
collection and its expected burden. TSA
published a Federal Register notice,
with a 60-day comment period soliciting
comments, of the following collection of
information on November 16, 2009, 74
FR 58967. TSA has received no
comments. The collections include: (1)
Applications from entities that wish to
become Certified Cargo Screening
Facilities (CCSF) or operate as a TSAapproved validation firm; (2) personal
information to allow TSA to conduct
security threat assessments on key
individuals employed by the CCSFs and
validation firms; (3) implementation of
a standard security program or
submission of a proposed modified
security program; (4) information on the
amount of cargo screened; (5)
recordkeeping requirements for CCSFs
and validation firms; and (6) submission
of validation reports to TSA. TSA is
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
9915
seeking the renewal of the ICR for the
continuation of the program in order to
secure passenger aircraft carrying cargo
by the deadlines set out in the
Implementing Recommendations of the
9/11 Commission Act of 2007.
DATES: Send your comments by April 5,
2010. A comment to OMB is most
effective if OMB receives it within 30
days of publication.
ADDRESSES: Interested persons are
invited to submit written comments on
the proposed information collection to
the Office of Information and Regulatory
Affairs, Office of Management and
Budget. Comments should be addressed
to Desk Officer, Department of
Homeland Security/TSA, and sent via
electronic mail to
oira_submission@omb.eop.gov or faxed
to (202) 395–6974.
FOR FURTHER INFORMATION CONTACT:
Joanna Johnson,, TSA Paperwork
Reduction Act (PRA) Officer, Office of
Information Technology (OIT), TSA–11,
Transportation Security Administration,
601 South 12th Street, Arlington, VA
20598–6011; telephone (571) 227–3651;
e-mail TSAPRA@dhs.gov.
SUPPLEMENTARY INFORMATION:
Comments Invited
In accordance with the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501
et seq.), an agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a valid OMB control
number. The ICR documentation is
available at https://www.reginfo.gov.
Therefore, in preparation for OMB
review and approval of the following
information collection, TSA is soliciting
comments to—
(1) Evaluate whether the proposed
information requirement is necessary for
the proper performance of the functions
of the agency, including whether the
information will have practical utility;
(2) Evaluate the accuracy of the
agency’s estimate of the burden;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including using
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Information Collection Requirement
Title: Certified Cargo Screening
Program.
Type of Request: Renewal of one
currently approved collection.
OMB Control Number: 1652–0053.
E:\FR\FM\04MRN1.SGM
04MRN1
]]>Agencies
[Federal Register Volume 75, Number 42 (Thursday, March 4, 2010)]
[Notices]
[Pages 9914-9915]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-4391]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of Organization, Functions, and Delegations of Authority of
the Department of Health and Human Services (45 FR 67772-76, dated
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as
amended most recently at 75 FR 7489-7490, dated February 19, 2010) is
amended to reflect the establishment of the Office of Infectious
Diseases, Centers for Disease Control and Prevention.
Section C-B, Organization and Functions, is hereby amended as
follows: After the mission statement for the Centers for Disease
Control and Prevention (C), insert the following:
Office of Infectious Diseases (CV). The mission of the Office of
Infectious Diseases (OID) is to lead, promote, and facilitate science,
programs, and policies to reduce the burden of infectious diseases in
the United States and globally.
Office of the Director (CVA). (1) Serves as the principal advisor
to the
[[Page 9915]]
CDC Director on infectious disease issues; (2) assists the CDC Director
in formulating and communicating strategic initiatives and policies;
(3) informs the CDC Director about key infectious disease issues; (4)
represents the CDC Director externally on infectious disease issues;
(5) provides strategic leadership to CDC's infectious disease national
centers; (6) develops overall strategic directions, sets priorities,
and promotes science, policies, and programs related to infectious
diseases; (7) ensures that agency-wide decisions on resource allocation
are aligned with infectious disease priorities; (8) works with
infectious disease national centers, other CDC centers and offices, and
public health partners to develop and implement infectious disease
goals and objectives; (9) identifies infectious disease issues of
public health importance and launches strategic initiatives to address
them, including developing shared goals and monitoring progress and
accomplishments; (10) recruits and supports an efficient, effective,
and vibrant work force, and fosters a safe and healthy work
environment; (11) enhances cooperation, collaboration, and partnerships
across multiple sectors, domestically and globally; (12) ensures
integrity, transparency, and excellence in public health science and
practice; (13) conducts ongoing evaluation and adjustment of infectious
disease activities to ensure optimal effectiveness and efficiency; (14)
promotes an environment that increases synergies and efficiencies and
reduces duplication within CDC's infectious disease programs; and (15)
provides direction and leadership for external and internal program
reviews of the infectious disease national centers' initiatives,
performance, and achievements.
Influenza Coordination Unit (CVA4). The mission of the Influenza
Coordination Unit (ICU) is to synchronize all aspects of CDC's pandemic
influenza preparedness and response from strategy through
implementation and evaluation. In carrying out its mission, the ICU:
(1) Serves as the principal advisor to the CDC Director and Deputy
Director for Infectious Diseases on pandemic influenza preparedness and
response activities, assisting the Director and Deputy Director for
Infectious Diseases in formulating and communicating strategic pandemic
initiatives and policies; (2) provides strategic leadership for CDC in
the areas of pandemic preparedness and response, including setting
priorities and promoting science, policies, and programs related to
pandemic influenza; (3) strategically manages a $150+ million budget
and allocates funds across the agency to ensure appropriate resources
for high priority areas; and (4) conducts ongoing evaluation and
adjustment of pandemic preparedness and response activities, in
coordination with the National Response Framework and other emergency
preparedness guidance, to ensure optimal public health effectiveness
and efficient use of human and fiscal resources.
Dated: February 23, 2010.
William P. Nichols,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2010-4391 Filed 3-3-10; 8:45 am]
BILLING CODE 4160-18-M
